MEPE is a novel regulator of growth plate cartilage mineralization

Bone

Volumn 51, Issue 3, 2012, Pages 418-430

  Staines, K A ^a   MacKenzie, N C W ^a   Clarkin, C E ^b   Zelenchuk, L ^c   Rowe, P S ^c   MacRae, V E ^a   Farquharson, C ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

ASARM; Chondrocyte; Growth plate; MEPE; Mineralization

Indexed keywords

ALKALINE PHOSPHATASE; ASARM PROTEIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; MESSENGER RNA; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BONE MINERALIZATION; CARTILAGE MINERALIZATION; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE; GENE OVEREXPRESSION; GROWTH PLATE; HISTOLOGY; MEPE GENE; METATARSAL BONE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

ALKALINE PHOSPHATASE; AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL MARKERS; BONE MATRIX; CALCIFICATION, PHYSIOLOGIC; CARTILAGE; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; GLYCOPROTEINS; GROWTH PLATE; METATARSAL BONES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; RNA, MESSENGER; TIBIA;

EID: 84864053375     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.06.022     Document Type: Article

References (69)

1. Kronenberg H.M. Developmental regulation of the growth plate. Nature 2003, 423:332-336.
2. Anderson H.C. Molecular biology of matrix vesicles. Clin Orthop Relat Res 1995, 266-280.
3. Meyer J.L. Can biological calcification occur in the presence of pyrophosphate?. Arch Biochem Biophys 1984, 231:1-8.
4. Rowe P.S., de Zoysa P.A., Dong R., Wang H.R., White K.E., Econs M.J., et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000, 67:54-68.
5. Fisher L.W., Fedarko N.S. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 2003, 44(Suppl. 1):33-40.
6. Qin C., Brunn J.C., Jones J., George A., Ramachandran A., Gorski J.P., et al. A comparative study of sialic acid-rich proteins in rat bone and dentin. Eur J Oral Sci 2001, 109:133-141.
7. Aplin H.M., Hirst K.L., Crosby A.H., Dixon M.J. Mapping of the human dentin matrix acidic phosphoprotein gene (DMP1) to the dentinogenesis imperfecta type II critical region at chromosome 4q21. Genomics 1995, 30:347-349.
8. Crosby A.H., Lyu M.S., Lin K., McBride O.W., Kerr J.M., Aplin H.M., et al. Mapping of the human and mouse bone sialoprotein and osteopontin loci. Mamm Genome 1996, 7:149-151.
9. Nampei A., Hashimoto J., Hayashida K., Tsuboi H., Shi K., Tsuji I., et al. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 2004, 22:176-184.
10. Argiro L., Desbarats M., Glorieux F.H., Ecarot B. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 2001, 74:342-351.
11. Petersen D.N., Tkalcevic G.T., Mansolf A.L., Rivera-Gonzalez R., Brown T.A. Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J Biol Chem 2000, 275:36172-36180.
12. Gowen L.C., Petersen D.N., Mansolf A.L., Qi H., Stock J.L., Tkalcevic G.T., et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 2003, 278:1998-2007.
13. David V., Martin A., Hedge A.M., Rowe P.S. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 2009, 150:4012-4023.
14. Martin A., David V., Laurence J.S., Schwarz P.M., Lafer E.M., Hedge A.M., et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008, 149:1757-1772.
15. Rowe P.S., Kumagai Y., Gutierrez G., Garrett I.R., Blacher R., Rosen D., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004, 34:303-319.
16. Rowe P.S., Matsumoto N., Jo O.D., Shih R.N., Oconnor J., Roudier M.P., et al. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone 2006, 39:773-786.
17. Guo R., Rowe P.S., Liu S., Simpson L.G., Xiao Z.S., Quarles L.D. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun 2002, 297:38-45.
18. Addison W.N., Nakano Y., Loisel T., Crine P., McKee M.D. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 2008, 23:1638-1649.
19. Stevens D.A., Hasserjian R.P., Robson H., Siebler T., Shalet S.M., Williams G.R. Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation. J Bone Miner Res 2000, 15:2431-2442.
20. Nilsson O., Parker E.A., Hegde A., Chau M., Barnes K.M., Baron J. Gradients in bone morphogenetic protein-related gene expression across the growth plate. J Endocrinol 2007, 193:75-84.
21. Heinrichs C., Yanovski J.A., Roth A.H., Yu Y.M., Domene H.M., Yano K., et al. Dexamethasone increases growth hormone receptor messenger ribonucleic acid levels in liver and growth plate. Endocrinology 1994, 135:1113-1118.
22. Mushtaq T., Bijman P., Ahmed S.F., Farquharson C. Insulin-like growth factor-I augments chondrocyte hypertrophy and reverses glucocorticoid-mediated growth retardation in fetal mice metatarsal cultures. Endocrinology 2004, 145:2478-2486.
23. Owen H.C., Miner J.N., Ahmed S.F., Farquharson C. The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol 2007, 264:164-170.
24. MacRae V.E., Farquharson C., Ahmed S.F. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol 2006, 189:319-328.
25. Haaijman A., Karperien M., Lanske B., Hendriks J., Lowik C.W., Bronckers A.L., et al. Inhibition of terminal chondrocyte differentiation by bone morphogenetic protein 7 (OP-1) in vitro depends on the periarticular region but is independent of parathyroid hormone-related peptide. Bone 1999, 25:397-404.
26. Shukunami C., Ishizeki K., Atsumi T., Ohta Y., Suzuki F., Hiraki Y. Cellular hypertrophy and calcification of embryonal carcinoma-derived chondrogenic cell line ATDC5 in vitro. J Bone Miner Res 1997, 12:1174-1188.
27. Zhang L., Conejo-Garcia J.R., Yang N., Huang W., Mohamed-Hadley A., Yao W., et al. Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem Biophys Res Commun 2002, 292:860-868.
28. MacRae V.E., Davey M.G., McTeir L., Narisawa S., Yadav M.C., Millan J.L., et al. Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick. Bone 2010, 46:1146-1155.
29. Prideaux M., Loveridge N., Pitsillides A.A., Farquharson C. Extracellular matrix mineralization promotes E11/gp38 glycoprotein expression and drives osteocytic differentiation. PLoS One 2012, 7:e36786.
30. Saito A., Hino S., Murakami T., Kanemoto S., Kondo S., Saitoh M., et al. Regulation of endoplasmic reticulum stress response by a BBF2H7-mediated Sec23a pathway is essential for chondrogenesis. Nat Cell Biol 2009, 11:1197-1204.
31. Hutchison M.R., Bassett M.H., White P.C. Insulin-like growth factor-I and fibroblast growth factor, but not growth hormone, affect growth plate chondrocyte proliferation. Endocrinology 2007, 148:3122-3130.
32. Gartland A., Mason-Savas A., Yang M., MacKay C.A., Birnbaum M.J., Odgren P.R. Septoclast deficiency accompanies postnatal growth plate chondrodysplasia in the toothless (tl) osteopetrotic, colony-stimulating factor-1 (CSF-1)-deficient rat and is partially responsive to CSF-1 injections. Am J Pathol 2009, 175:2668-2675.
33. Lee E.R., Lamplugh L., Shepard N.L., Mort J.S. The septoclast, a cathepsin B-rich cell involved in the resorption of growth plate cartilage. J Histochem Cytochem 1995, 43:525-536.
34. Altaf F.M., Hering T.M., Kazmi N.H., Yoo J.U., Johnstone B. Ascorbate-enhanced chondrogenesis of ATDC5 cells. Eur Cell Mater 2006, 12:64-69.
35. Anderson H.C., Chacko S., Abbott J., Holtzer H. The loss of phenotypic traits by differentiated cells in vitro. VII. Effects of 5-bromodeoxyuridine and prolonged culturing on fine structure of chondrocytes. Am J Pathol 1970, 60:289-312.
36. Chacko S., Abbott J., Holtzer S., Holtzer H. The loss of phenotypic traits by differentiated cells. VI. Behavior of the progeny of a single chondrocyte. J Exp Med 1969, 130:417-442.
37. Nameroff M., Holtzer H. The loss of phenotypic traits by differentiated cells. IV. Changes in polysaccharides produced by dividing chondrocytes. Dev Biol 1967, 16:250-281.
38. Abbott J., Holtzer H. The loss of phenotypic traits by differentiated cells. 3. The reversible behavior of chondrocytes in primary cultures. J Cell Biol 1966, 28:473-487.
39. Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999, 5:623-628.
40. Zijlstra A., Aimes R.T., Zhu D., Regazzoni K., Kupriyanova T., Seandel M., et al. Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3). J Biol Chem 2004, 279:27633-27645.
41. Nagai H., Aoki M. Inhibition of growth plate angiogenesis and endochondral ossification with diminished expression of MMP-13 in hypertrophic chondrocytes in FGF-2-treated rats. J Bone Miner Metab 2002, 20:142-147.
42. Anderson H.C., Sipe J.B., Hessle L., Dhanyamraju R., Atti E., Camacho N.P., et al. Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am J Pathol 2004, 164:841-847.
43. Hessle L., Johnson K.A., Anderson H.C., Narisawa S., Sali A., Goding J.W., et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A 2002, 99:9445-9449.
44. Johnson K., Polewski M., van E.D., Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol 2005, 25:686-691.
45. Nurnberg P., Thiele H., Chandler D., Hohne W., Cunningham M.L., Ritter H., et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 2001, 28:37-41.
46. Sohn P., Crowley M., Slattery E., Serra R. Developmental and TGF-beta-mediated regulation of Ank mRNA expression in cartilage and bone. Osteoarthritis Cartilage 2002, 10:482-490.
47. Rowe P.S. The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 2004, 15:264-281.
48. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26:345-348.
49. Sitara D., Razzaque M.S., Hesse M., Yoganathan S., Taguchi T., Erben R.G., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004, 23:421-432.
50. Sitara D., Kim S., Razzaque M.S., Bergwitz C., Taguchi T., Schuler C., et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008, 4:e1000154.
51. Yu X., White K.E. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 2005, 16:221-232.
52. Ogbureke K.U., Fisher L.W. Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 2004, 83:664-670.
53. Boukpessi T., Gaucher C., Leger T., Salmon B., Le F.J., Willig C., et al. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin. Am J Pathol 2010, 177:803-812.
54. Bresler D., Bruder J., Mohnike K., Fraser W.D., Rowe P.S. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 2004, 183:R1-R9.
55. Atkins G.J., Rowe P.S., Lim H.P., Welldon K.J., Ormsby R., Wijenayaka A.R., et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res 2011, 26:1425-1436.
56. Anderson H.C. Matrix vesicles and calcification. Curr Rheumatol Rep 2003, 5:222-226.
57. Addison W.N., Azari F., Sorensen E.S., Kaartinen M.T., McKee M.D. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 2007, 282:15872-15883.
58. Wang J., Zhou H.Y., Salih E., Xu L., Wunderlich L., Gu X., et al. Site-specific in vivo calcification and osteogenesis stimulated by bone sialoprotein. Calcif Tissue Int 2006, 79:179-189.
59. Yadav M.C., Simao A.M., Narisawa S., Huesa C., McKee M.D., Farquharson C., et al. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res 2011, 26:286-297.
60. Huesa C., Yadav M.C., Finnila M.A., Goodyear S.R., Robins S.P., Tanner K.E., et al. PHOSPHO1 is essential for mechanically competent mineralization and the avoidance of spontaneous fractures. Bone 2011, 48:1066-1074.
61. Sprowson A.P., McCaskie A.W., Birch M.A. ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion. J Orthop Res 2008, 26:1256-1262.
62. Hayashibara T., Hiraga T., Yi B., Nomizu M., Kumagai Y., Nishimura R., et al. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res 2004, 19:455-462.
63. Boskey A.L., Chiang P., Fermanis A., Brown J., Taleb H., David V., et al. MEPE's diverse effects on mineralization. Calcif Tissue Int 2009, 86(1):42-46.
64. Rowe P.S. The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled. Cell Biochem Funct 2012, 30(5):355-375.
65. Rowe P.S., Garrett I.R., Schwarz P.M., Carnes D.L., Lafer E.M., Mundy G.R., et al. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 2005, 36:33-46.
66. Liu S., Rowe P.S., Vierthaler L., Zhou J., Quarles L.D. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 2007, 192:261-267.
67. Zelzer E., McLean W., Ng Y.S., Fukai N., Reginato A.M., Lovejoy S., et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 2002, 129:1893-1904.
68. Stickens D., Behonick D.J., Ortega N., Heyer B., Hartenstein B., Yu Y., et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004, 131:5883-5895.
69. Pirotte S., Lamour V., Lambert V., varez Gonzalez M.L., Ormenese S., Noel A., et al. Dentin matrix protein 1 induces membrane expression of VE-cadherin on endothelial cells and inhibits VEGF-induced angiogenesis by blocking VEGFR-2 phosphorylation. Blood 2011, 117:2515-2526.